The clinical scenario, which is based on systolic blood pressure (SBP) upon admission, is useful for classifying and determining initial treatment for acute heart failure (HF). However, the prognostic significance of SBP following the initial treatment is unclear.
H ypertension is associated with incident heart failure (HF), 1) and is more frequently observed in patients with HF with preserved ejection fraction (HFpEF) than in those with HF with reduced ejection fraction (HFrEF).
2) Hypertension is the most important cause of HFpEF, with a prevalence of 60% to 89% from large controlled trials. 3) In the general population, higher systolic blood pressure (SBP) is one of the strongest predictors of all-cause death, 4) and lower resting SBP is associated with lower all-cause mortality. 5) On the other hand, initial SBP upon admission in patients hospitalized for acute heart failure syndromes (AHFS) is quite different; the higher SBP on admission predicts better prognosis. 6) The current guidelines state that urgent/immediate evaluation (e.g., clinical profile, congestion/hypoperfusion, and/or clinical scenario) and treatment in patients with AHFS is required. [7] [8] [9] Although the clinical profile and congestion/hypoperfusion classifications are widely accepted, the classification based on SBP is superior due to its larger applicability in clinical practice because it shows less geographic variation.
9) The clinical scenario is based on initial SBP on admission and other symptoms, and is one of the most commonly used clinical classifications. 10) In summary, AHFS patients are divided into five groups:
SATO, ET AL clinical scenario 1 (SBP > 140 mmHg with dyspnea and/ or congestion), clinical scenario 2 (SBP 100-140 mmHg with dyspnea and/or congestion), clinical scenario 3 (SBP < 100 mmHg with dyspnea and/or congestion), clinical scenario 4 (signs of acute coronary syndrome with dyspnea and/or congestion), and clinical scenario 5 (isolated right ventricular failure). 10) This classification is useful in determining initial treatment (e.g., non-invasive positive pressure ventilation, vasodilators, inotropes, and diuretics). This urgent/immediate approach shortens the length of hospital stay and reduces in-hospital mortality in terms of shortening the time to the start treatment. 11, 12) However, it is still unclear whether clinical scenario predicts postdischarge mortality or not. In addition, hemodynamics, including SBP, change drastically upon initial treatment and the prognostic impact of subsequent SBP is also unknown, especially in HFpEF patients.
We aimed to compare the prognostic impact of SBP on admission, on the following day, and at discharge using the recruited data of hospitalized HFpEF patients enrolled in the Japanese Heart Failure Syndrome with Preserved Ejection Fraction (JASPER) registry.
Methods

Patient recruitment:
The JASPER registry is a multicenter, observational, prospective cohort that includes consecutive patients aged !20 years requiring hospitalization with a diagnosis of acute HF according to the Framingham criteria 13) by at least two experienced cardiologists. Preserved left ventricular (LV) systolic function was defined as LV ejection fraction (LVEF) !50% by the modified Simpson method or LV fractional shortening !25% by echocardiography. Patients with acute coronary syndrome, receiving hemodialysis, or with a history of heart transplantation were excluded. The patients' demographic data, including comorbid conditions, clinical signs, laboratory and echocardiographic data, and length of hospital stay, were obtained. Follow-up was performed at discharge, as well as at 12 and 24 months after discharge, by dedicated coordinators and investigators through direct contact with patients or their physicians at the hospital or outpatient clinic, telephone interview of patients or, if deceased, family members, and by mail. 14) In the current study, because patient information was anonymized and de-identified prior to analysis, written informed consent was not obtained from each patient. However, the study was publicized by posting a summary of the protocol on the National Cerebral and Cardiovascular Center website where a notice clearly informed patients of their right to refuse enrollment. These procedures for informed consent and enrollment were in accordance with the detailed regulations described in the guidelines, and this study, including the procedure for enrollment, was approved by the Institutional Review Board of each site and registered under the Japanese UMIN Clinical Trials Registration (UMIN000010601). 14) All investigators are presented in the previous report.
14)
The patient flow chart of the present analysis is shown in Figure 1 . The exclusion criteria were as follows: patients who died during the first hospitalization and/or patients whose SBP on the day following hospitalization was unknown. Of 535 patients enrolled in the JASPER registry, 10 patients met the exclusion criteria. Finally, 525 patients were enrolled in this present analysis. We examined the patients' demographic data, in-hospital treatment, length of hospital stay, laboratory and echocardiographic data, and prognosis after discharge. This pre-sent analysis had two primary endpoints: (1) all-cause death and (2) all-cause death or rehospitalization for HF. Statistical analysis: Normality was confirmed using the Shapiro-Wilk test in each group. Parametric variables were presented as mean ± standard deviation, nonparametric variables were presented as median (interquartile range), and categorical variables were expressed as numbers and percentages. Parametric variables were compared using the analysis of variance (ANOVA). Equality was judged using Levene's test. If the data were equal, the ANOVA was followed by the Tukey's honestly significant difference test. If data were not equal, the Games-Howell post-hoc test was used. Non-parametric variables were compared using the Kruskal-Wallis test followed by the Steel-Dwass post-hoc test. The Chi-square test was used for comparisons of categorical variables and was followed by the Fisher's exact test if appropriate. The Spearman's rank correlation coefficient was used to discover the strength of links among SBP measured at each time. The Kaplan-Meier analysis was used for presenting the two primary endpoints, and the log-rank test was used for initial comparisons. The proportional hazards assumption for the model was checked by examining log minus-log transformed data. The curves helped in identifying the nonproportionality patterns in hazard function, such as convergence (the difference in risk among the groups decreases with time), divergence, or the crossing of the curves. The Cox proportional hazard analyses were used to evaluate SBP classification as a predictor of all-cause death and the composite endpoint of all-cause death or rehospitalization for HF. Univariate factors that had a P value of < 0.05 except for factors below were entered into the multivariate model. The presence of a history of hypertension, diastolic blood pressure, heart rate, LV outflow tract velocity time integral (LVOT-VTI), medications, and initial treatments were not entered into the multivariate model because it was presumed to be strongly related to SBP, and had multicollinearity with SBP. 9) In order to assess the prognostic impact of any excessive blood pressure-lowering effect of initial treatments, the univariable Cox proportional hazard analysis with subgroups of SBP was performed on the following day. A P value of < 0.05 was considered statistically significant for all comparisons. The Kruskal-Wallis test and the Steel-Dwass post-hoc test was performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). 15) All other analyses were performed using SPSS ver. 25 (IBM, Armonk, NY, USA).
Results
In the follow-up period of a median of 732 days, there were 82 all-cause deaths and 128 rehospitalizations for HF. In the Kaplan-Meier analysis (Figures 2, 3) , SBP on the following day showed that patients with low SBP (SBP < 100 mmHg) had the highest all-cause death ( Thus, we divided the 525 patients into three groups based on their SBP on the day following hospitalization (Figure 1 ): high group (SBP > 140 mmHg, n = 72, 13.7%), normal group (100 !SBP !140 mmHg, n = 379, 72.2%), and low group (SBP < 100 mmHg, n = 74, 14.1%). We compared patients' clinical characteristics among the groups (Table I ). There were no statistical differences in age, sex, or body mass index among the three groups. The prevalence of New York Heart Association (NYHA) functional class III or IV on admission was the highest in the high group, followed by the low group and the normal group (high, normal, low; 91.3%, 74.4%, and 80.9%, P = 0.007). In contrast, NYHA class at discharge did not differ among the groups. Regarding vital signs, the low group showed a higher heart rate both on admission and at discharge (P = 0.003 and P = 0.047, respectively) and lower SBP both on admission and at discharge (P < 0.001 and P < 0.001, respectively). According to past medical history, the low group demonstrated a higher prevalence of atrial fibrillation (47.8%, 63.9%, and 67.1%, P = 0.026) as well as a lower prevalence of diabetes mellitus/impaired glucose tolerance (52.8%, 38.7%, and 26.0%, P = 0.004) and hypertension (87.5%, 78.8%, and 62.2%, P = 0.001) than the normal and high groups. The usage of β blockers, angiotensin converting-enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs), loop diuretics, digitalis, and nitrates were comparable among the groups on admission. Meanwhile, the use of spironolactone was higher (19.4%, 13.5%, and 27.0%, P = 0.011) and the use of calcium channel blockers was lower (56.9%, 54.9%, and 29.7%, P < 0.001) in the low group. These three groups obtained similar intravenous treatments, except for intravenous diuretics, which tended to be used less in the low group. Invasive positive pressure ventilation was performed most frequently in the low group (2.8%, 0.8%, and 5.4%, P = 0.015). The length of hospital stay was the longest in the high group, followed by the low and normal groups (20.0 days, 15.5 days, and 15.0 days, P = 0.002).
The laboratory and echocardiographic data on admission are presented in Table II . In the laboratory data, there was no statistical difference in plasma levels of B-type natriuretic peptide among the three groups (P = 0.880). There were significant differences in the hemoglobin levels (10.1 g/dL, 11.1 g/dL, and 10.9 g/dL, P = 0.008), sodium (141.0 mEq/L, 141.0 mEq/L, and 140.0 mEq/L, P = 0.047), creatinine (1.25 mg/dL, 1.03 mg/dL, and 0.93 mg/ dL, P = 0.016), C-reactive protein (0.48 mg/dL, 0.45 mg/ dL, and 0.24 mg/dL, P = 0.047) and albumin (3.5 g/dL, 3.7 g/dL, and 3.7 g/dL, P = 0.045). The echocardiographic data revealed a lower LVOT-VTI in the low group than those in the normal and high groups (23.3 cm, 19.4 cm, and 16.4 cm, P = 0.001). In contrast, there were no significant differences in other echocardiographic parameters, including LVEF, inferior vena cava diameter, and tricuspid regurgitation pressure gradient.
In the Spearman's rank correlation coefficient (Table  III) , there were only weak correlations between SBP measured at each time (between on admission, on the fol-SATO, ET AL lowing day, and at discharge, P < 0.001, respectively).
The results of the Cox proportional hazard analysis with the normal SBP (100 !SBP !140 mmHg) as reference for predicting all-cause death and the composite endpoint of all-cause death or rehospitalization for HF are summarized in Table IV . In the univariable analysis, the low SBP (SBP < 100 mmHg) on the following day was associated with all-cause death (hazard ratio (HR) 2.142, 95% confidence interval (CI) 1.275-3.599, P = 0.004) and the composite endpoint (HR 1.610, 95% CI 1.109-2.336, P = 0.012). The low SBP on admission and at discharge and the high SBP (> 140 mmHg) at each time did not show the statistical significance for predicting both of the primary endpoints. After adjusting for age, sex, NYHA functional class on admission III or IV, atrial fibrillation, diabetes mellitus/impaired glucose tolerance, hemoglobin, sodium, creatinine, C-reactive protein, and albumin, the low SBP on the following day remained the statistical sig- nificance in predicting all-cause death (HR 1.868, 95% CI 1.024-3.407, P = 0.042), and the composite endpoint (HR 1.660, 95% CI 1.103-2.500, P = 0.015). Initial treatments were not associated with post-discharge prognosis, regardless of the presence or absence of excessive blood pressure-lowering effect (Table V) . SBP on admission SBP on the following day SBP at discharge SBP on admission -r = 0.312 r = 0.277 P < 0.001 P < 0.001 SBP on the following day r = 0.312 -r = 0.383 P < 0.001 P < 0.001 SBP at discharge r = 0.277 r = 0.383 -P < 0.001 P < 0.001 SBP indicates systolic blood pressure.
SATO, ET AL
Discussion
To the best of our knowledge, this analysis is the first to report that SBP on the day following hospitalization, but neither SBP on admission nor SBP at discharge, is an independent predictor of post-discharge prognosis in hospitalized patients with HFpEF.
The prognostic impact of SBP on HFpEF might be considered different from that on HFrEF because patients with HFpEF differ from those with HFrEF in several aspects (e.g., age, sex, comorbidity, HF etiology). 16, 17) In hospitalized patients with HFrEF, higher SBP on admission is an independent predictor of lower mortality risk after discharge, suggesting the existence of the "SBP paradox." 18) Namely, contrary to the general population, higher SBP in HF patients has a positive impact on prognosis. 19) The "SBP paradox" is reported to persist in the chronic phase in patients with HFrEF. 20) On the other hand, the prognostic impact of SBP on HFpEF remains controversial. Several studies have reported that SBP in the chronic phase in outpatients with HFpEF is not associated with all-cause mortality [21] [22] [23] while other large registries have found that low SBP at discharge was associated with higher all-cause mortality in hospitalized patients with HFpEF. 24) In addition, in AHFS patients with HFpEF, the highest quartile of SBP on admission is reported to be associated with lower short-and long-term all-cause mortality compared to those with the lowest quartile of SBP.
25) It is also unclear whether SBP shows a linear association or a J/U-shaped association with prognosis. Additionally, the timing for SBP evaluation might be important in predicting prognosis.
This analysis could not completely deny the prognostic impact of SBP on admission and at discharge because of the relatively small number of participants. However, SBP on the following day significantly predicted the post-SBP ON THE FOLLOWING DAY IN HFpEF PATIENTS discharge prognosis. Since this analysis was based on the prospective observational registry, it was difficult to fully clarify why SBP on the following day predicted the prognosis. As a plausible explanation, several studies have reported the concept of reactive hypertension, which is the ability to raise blood pressure in the acute phase of HF. 18, 26) Namely, higher SBP under acute physiologic stress reflects the functional cardiac reserve mediated by an ability to achieve a vasoconstrictive response and/or a greater myocardial contractile reserve, resulting in a greater cardiac output. 26) Contractile reserve is reported to be impaired not only in patients with HFrEF 27) but also in those with HFpEF.
28) The myocardial contractile reserve is mainly regulated by the Frank-Starling mechanism, 29, 30) force-frequency relationship, 31, 32) and sympathetic nerve stimulation. 33) Patients in the low group probably had more impaired mechanisms and therefore, demonstrated lower SBP and LVOT-VTI. Thus, patients presenting higher SBP in the acute phase of HF have early or midstage disease, while those with lower SBP even in acute stressful condition have advanced or end-stage disease and undergo worse prognosis. 18, 19, 26, 34) Thus, SBP on admission (super acute phase) and on the following day (sub-acute phase) reflects functional cardiac reserve and is superior to SBP at discharge (chronic phase) in predicting prognosis. Although we could not explain the reason why SBP on the following day had the stronger association with post-discharge prognosis than SBP on admission, we assume that SBP on admission (super acute phase) is too unstable due to multiple factors (e.g., neuro-hormonal and cytokine activation, subendocardial ischemia, progressive valvular regurgitation, and peripheral resistance) 34) while SBP on the following day (sub-acute phase) reflects functional cardiac reserve more properly than SBP on admission (super acute phase). In addition, initial treatments were not associated with post-discharge prognosis and did not show interactions with low SBP in predicting postdischarge prognosis. Moreover, the existence of atrial fibrillation, which was most common in the low group, can decrease cardiac output by up to 25% in patients with diastolic dysfunction, 35) and is associated with adverse prognosis in HFpEF patients. 36, 37) The increased usage of invasive positive pressure ventilation, which indicates the severity of HF, was highest in the low group.
The prognostic significance of the high group needs more investigation. In the present analysis, we found several results showing the (inversed) J/U-shaped phenomenon (e.g., NYHA functional class III or IV on admission, hemoglobin, use of invasive positive pressure ventilation, and length of hospital stay). In addition, the high group had the highest prevalence of hypertension and diabetes mellitus. This may suggest an atherosclerotic change and an increased risk of future cardiovascular and renal diseases. [38] [39] [40] [41] Considering cardiac physiology, mean blood pressure (MBP) is determined by cardiac output (CO), systemic vascular resistance (SVR), and central venous pressure (CVP): MBP = (CO × SVR) + CVP. 20) High SBP may reflect not only preserved CO, but also elevated SVR due to the atherosclerosis. 20, 42) Furthermore, it is necessary to follow up the participants for longer periods to estimate SATO, ET AL the impact of high SBP.
4)
Study strengths and limitations: There were several strengths to the present analysis. First, the classification investigated was similar to the clinical scenario. Clinicians can select the appropriate initial treatment on admission and estimate post-discharge prognosis on the following day by repeating the evaluation of SBP. Second, the classification was simple, based on only SBP. This simplified approach is easy to use for not only cardiologists, but also for every clinical physician. On the other hand, there were some limitations in the present analysis. The general limitations of the JASPER registry were described in the previous article. 14) Focusing on SBP, data on usual SBP and disease duration of hypertension were not available in the JASPER registry data. A higher number of participants was needed to analyze the detailed causes of death, especially those related to hypertension, such as stroke and ischemic heart disease.
Conclusion
Classification based on SBP on the day following initial treatment predicts post-discharge prognosis in hospitalized patients with HFpEF.
